CANbridge Pharmaceuticals Inc. (HK:1228) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
CANbridge Pharmaceuticals Inc. reports significant headway in their drug pipeline for rare diseases, with the commercial launch of Hunterase® and Livmarli® in China and the progression of CAN103 through clinical trials. The company has also ventured into gene therapy, licensing a novel technology for Duchenne Muscular Dystrophy treatment, and expects to submit a New Drug Application for CAN103 by the end of 2024.
For further insights into HK:1228 stock, check out TipRanks’ Stock Analysis page.